Nov 06, 2024 / 01:00PM GMT
Carlos Sousa - Ultimovacs ASA - Chief Executive Officer
Good afternoon and welcome to Ultimovacs third quarter, 2024 business update and financial results.
My name is Carlos de Sousa and I'm the CEO. as usual I have with me and BHE our Chief Medical Officer and Hans Vaso Aid, our Chief Financial Officer, if we can move to the next slide, just to show you briefly our disclaimer and we continue to the next slide.
So I will make a brief introduction. We will talk then about the clinical update for UV One brief words about our novel drug conjugation platform, the financial update and the news flow. So if we can move to the next slide, this quarter was again, we had a disappointing news about the results from our focus trial in head and neck cancer.
We knew that it was a difficult target to head and neck cancer is a very difficult cancer to treat. even the standard of care has very low efficacy. But anyway, we were still disappointed, but as a company, we are still committed to bringing UV one across the next important data point. That is the Duva redoubt that we expect in the first
Q3 2024 Ultimovacs ASA Earnings Call Transcript
7 days ago
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers